Effect of isopropyl myristic acid ester on the physical characteristics and in vitro release of etoposide from PLGA microspheres

AAPS PharmSciTech

Volumn 1, Issue 4, 2000, Pages

  Schaefer, Matthew J ^a   Singh, Jagdish ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

Author keywords

Etoposide; In vitro release; Isopropyl myristic acid ester; PLGA microspheres; Scanning electron microscopy

Indexed keywords

ETOPOSIDE; MICROSPHERE; MYRISTIC ACID ISOPROPYL ESTER; POLYGLACTIN; ESTER; LACTIC ACID; MYRISTIC ACID DERIVATIVE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG RELEASE; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; PARTICLE SIZE; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SOLVENT EXTRACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG FORMULATION; METABOLISM; METHODOLOGY; STATISTICS;

DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; ESTERS; ETOPOSIDE; LACTIC ACID; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; MYRISTATES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS;

EID: 23144466483     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt010432     Document Type: Article

References (24)

1. Gupta PK. Drug targeting in cancer chemotherapy: A clinical perspectives. J Pharm Sci. 1990;79:457-465.
2. Burger JJ, Tomlinson E, Mulder EMA, McVie JG. Albumin microspheres for intra-arterial tumor targeting. I. Pharmaceutical aspects. Int J Pharm. 1985;23:333-344.
3. Schaefer M, Singh J. Etoposide microspheres for targeting to the lung. Proc Int Symp Control Rel Bioact Mater. 1998;25:441-442.
4. Tripathi KP, Singh J. Aminophylline targeting to lung: optimization of the size and drug loading of albumin microspheres. J Microencapsulation. 1992;9:229-235.
5. Kanke M, Simmons GH, Weiss DL, Bivins BA, DeLuca PP. Clearance of 141 Ce-labelled microspheres in specific organs following intravenous and intra-arterial administration in beagle dogs. J Pharm Sci. 1980;69:755-762.
6. Illum L, David SS. Targeting of colloidal particles to the bone marrow. Life Sci. 1987;40:1553-1560.
7. Guiot P, Couvreur M. Polymeric Nanoparticles and Microspheres. Boca Raton, FL: CRC Press; 1986.
8. David SS, Hunneyball IM, Illum L, Ratcliffe JH, Smith A, Wilson CG. Recent advances in the use of microspheres for targeted therapy. Drugs Exp Clin Res. 1985;9:633-640.
9. David SS, Illum L, McVie JG, Tomlinson E. Microspheres and Drug Therapy. New York, NY: Elsevier; 1984.
10. Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer. 1998;34:1514-1521.
11. Slevin M. The clinical pharmacology of etoposide. Cancer. 1991;67:31-39.
12. O'Dwyer P, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide: current status of an active anticancer drug. N Engl J Med. 1985;312:692-698.
13. Wolf SN, Grosh WW, Prater K, et al. In vitro pharmacodynamic evaluation of VP-16213 and implications for chemotherapy, Cancer Chemother Pharmacol. 1987;19:246-249.
14. Lewis DD. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, eds. Biodegradable Polymers as Drug Delivery Systems. New York, NY: Marcel Dekker; 1990:1-41.
15. Jain R, Navnit HS, Mailick AW, Rhodes CT. Controlled delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev Ind Pharm. 1998;24:703-727.
16. Kostanski JW, DeLuca PP. A novel in vitro release technique for peptide-containing biodegradable microspheres, PharmSciTech. 2000; 1(1) Article 4. Available at http://www.pharmscitech.com.
17. Ravivarapu HB, Moyer KL, Dunn RL. Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant, PharmSciTech. 2000; 1(1) Article 1. Available at http://www.pharmscitech.com.
18. Kostanaski JW, Dani BA, Reynolds G-A, Bowers CY, DeLuca PP. Evaluation of Orntide microspheres in rat animal model and correlation to in vitro release profiles, PharmSciTech. 2000; 1(4) Article 27. http://www.pharmscitech.com.
19. Gebrekidan S, Woo BH, DeLuca PP. Formulation and in vitro transfection efficiency of poly (d, l- lactide-co-glycolide) microspheres containing plasmid DNA for gene delivery, PharmSciTech. 2000; 1(4) Article 28. http://www.pharmscitech.com.
20. Park TG. Degradation of poly(lactic-co-glycolic acid) microspheres: effect of co-polymer composition. Biomaterials. 1995;16:1123-1130.
21. Sato H, Wang YM, Adachi I, Horikoshi I. Pharmacokinetic study of taxol-loaded poly(lactic-co-glycolic acid) microspheres containing isopropyl myristate after targeted delivery to the lung in mice. Biol Pharm Bull. 1996;19:1596-1601.
22. Wang YW, Sato H, Adachi I, Horikoshi I. Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. Chem Pharm Bull (Tokyo). 1996;44:1935-1940.
23. Juni K, Ogata J, Matsui N, Kubota M, Nakano M. Modification of the release rate of aclarabicin from polylactic acid microspheres. Chem Pharm Bull (Tokyo). 1985;33:1734-1738.
24. Chow D, Shah J. Stability-indicating high performance liquid chromatography of etoposide at various pH conditions using a reversed-phase octyl column. J Chromatogr. 1987;396:217-223.